Comparative Pharmacology
Head-to-head clinical analysis: BENZEDRINE versus DYANAVEL XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZEDRINE versus DYANAVEL XR.
BENZEDRINE vs DYANAVEL XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzedrine (racemic amphetamine) releases dopamine and norepinephrine from presynaptic neurons, blocks their reuptake, and inhibits monoamine oxidase, increasing synaptic monoamine levels.
Dyanavel XR is a central nervous system stimulant that increases the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and increasing their release, thereby enhancing neurotransmission in the brain regions involved in attention and impulse control.
Oral: 5-10 mg once or twice daily, maximum 40 mg/day. Intramuscular: 5-10 mg every 30-60 minutes as needed, maximum 40 mg/day.
Initial dose: 5 mg orally once daily in the morning. Maximum dose: 20 mg once daily. May increase by 5–10 mg weekly based on tolerability and response.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults (range 4-8 hours). Clinically, duration of action correlates with half-life, but tolerance may develop with repeated dosing.
Mean terminal elimination half-life is approximately 8-10 hours for d-amphetamine and 12-14 hours for l-amphetamine; the extended-release formulation maintains therapeutic concentrations for 12-14 hours.
Renal (30-40% unchanged, pH-dependent), with minor biliary/fecal elimination. At acidic urine pH, elimination half-life is shortened; at alkaline pH, reabsorption increases.
Approximately 30-50% of a dose is excreted unchanged in urine; remainder as metabolites (primarily hippuric acid) via renal elimination. Fecal excretion is minimal.
Category C
Category C
CNS Stimulant
CNS Stimulant